======= KDM3B =======
== Gene Information ==
* **Official Symbol**: KDM3B
* **Official Name**: lysine demethylase 3B
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=51780|51780]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q7LBC6|Q7LBC6]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=KDM3B&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20KDM3B|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/609373|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Histone demethylase that specifically demethylates 'Lys- 9' of histone H3, thereby playing a central role in histone code. Demethylation of Lys residue generates formaldehyde and succinate. May have tumor suppressor activity. {ECO:0000269|PubMed:16603237}.
|JmjC|
|response to cisplatin|
|histone demethylase activity (H3-K9 specific)|
|histone H3-K9 demethylation|
|antioxidant activity|
|dioxygenase activity|
|histone lysine demethylation|
|histone demethylation|
|protein demethylation|
|protein dealkylation|
|demethylation|
|chromatin DNA binding|
|transcription regulatory region sequence-specific DNA binding|
|cellular oxidant detoxification|
|response to antineoplastic agent|
|cellular detoxification|
|chromatin|
|detoxification|
|cellular response to toxic substance|
|histone modification|
|covalent chromatin modification|
|response to toxic substance|
|chromatin organization|
|oxidation-reduction process|
|response to drug|
|chromosome organization|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp215|Colchicine 0.009μM R05 exp215]]|-2.1|
|[[:results:exp245|UM0011500 5μM R05 exp245]]|-1.73|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|1.72|
|[[:results:exp443|SNS-032 15μM R08 exp443]]|1.73|
|[[:results:exp453|B02 10μM R08 exp453]]|1.78|
|[[:results:exp93|DABN racemic mixture R03 exp93]]|1.8|
|[[:results:exp239|PFI-2 4μM R05 exp239]]|1.8|
|[[:results:exp341|BRD2 inhibitor II 20μM R07 exp341]]|1.81|
|[[:results:exp419|Tunicamycin 0.04 to 0.075μM on day4 R07 exp419]]|1.83|
|[[:results:exp234|Ethanol 0.01 R05 exp234]]|1.91|
|[[:results:exp525|Sulforaphane 9μM R08 exp525]]|1.91|
|[[:results:exp451|Atovaquone 15μM R08 exp451]]|1.96|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|1.96|
|[[:results:exp116|AICAR 240μM R03 exp116]]|1.99|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|2.04|
|[[:results:exp274|Citral 50μM R06 exp274]]|2.06|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|2.06|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|2.06|
|[[:results:exp326|CCT251545 20μM R07 exp326]]|2.13|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|2.16|
|[[:results:exp134|MS023 2μM R03 exp134]]|2.21|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|2.33|
|[[:results:exp502|Milciclib 2μM R08 exp502]]|2.34|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|2.43|
|[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|2.56|
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|2.67|
|[[:results:exp439|QNZ 0.01μM R08 exp439]]|2.76|
|[[:results:exp115|A-366 10μM R03 exp115]]|2.93|
|[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|2.95|
^Gene^Correlation^
|[[:human genes:m:mapkap1|MAPKAP1]]|0.419|
|[[:human genes:u:urm1|URM1]]|0.402|
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 15931
* **Expression level (log2 read counts)**: 7.82
{{:chemogenomics:nalm6 dist.png?nolink |}}